QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
NASDAQ:KTTA

Pasithea Therapeutics - KTTA Stock Forecast, Price & News

$0.70
+0.04 (+6.03%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.65
$0.73
50-Day Range
$0.55
$1.03
52-Week Range
$0.54
$1.54
Volume
552,642 shs
Average Volume
123,073 shs
Market Capitalization
$20.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

KTTA stock logo

About Pasithea Therapeutics (NASDAQ:KTTA) Stock

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Receive KTTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KTTA Stock News Headlines

KTTA Pasithea Therapeutics Corp.
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Pasithea Therapeutics Corp. (KTTA)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Pasithea Therapeutics Acquires AlloMek Therapeutics
See More Headlines
Receive KTTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KTTA Company Calendar

Today
1/31/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KTTA
Fax
N/A
Employees
1
Year Founded
N/A

Profitability

Net Income
$-2,170,000.00
Net Margins
-3,133.55%
Pretax Margin
-3,133.55%

Debt

Sales & Book Value

Annual Sales
$20,000.00
Book Value
$2.23 per share

Miscellaneous

Free Float
27,348,000
Market Cap
$20.56 million
Optionable
Not Optionable
Beta
-0.04

Key Executives

  • Dr. Lawrence Steinman BA (Age 74)
    M.D., Exec. Chairman & Co-Founder
    Comp: $72.92k
  • Dr. Tiago Reis Marques (Age 45)
    CEO & Director
    Comp: $243.75k
  • Mr. Daniel H. Schneiderman (Age 44)
    Chief Financial Officer
  • Dr. Yassine Bendiabdallah Ph.D. (Age 37)
    COO & Head of UK Clinics













KTTA Stock - Frequently Asked Questions

How have KTTA shares performed in 2023?

Pasithea Therapeutics' stock was trading at $0.6417 at the beginning of the year. Since then, KTTA stock has increased by 9.5% and is now trading at $0.7029.
View the best growth stocks for 2023 here
.

When did Pasithea Therapeutics IPO?

(KTTA) raised $17 million in an initial public offering on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share.

What is Pasithea Therapeutics' stock symbol?

Pasithea Therapeutics trades on the NASDAQ under the ticker symbol "KTTA."

How do I buy shares of Pasithea Therapeutics?

Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pasithea Therapeutics' stock price today?

One share of KTTA stock can currently be purchased for approximately $0.70.

How much money does Pasithea Therapeutics make?

Pasithea Therapeutics (NASDAQ:KTTA) has a market capitalization of $20.56 million and generates $20,000.00 in revenue each year.

How can I contact Pasithea Therapeutics?

Pasithea Therapeutics' mailing address is 1111 Lincoln Road Suite 500, Miami Beach FL, 33139. The official website for the company is www.pasithea.com. The company can be reached via phone at 702-514-4174 or via email at lwilson@insitecony.com.

This page (NASDAQ:KTTA) was last updated on 1/31/2023 by MarketBeat.com Staff